N-((1S)-1-((1R)-2-(((4'S)-8'-chloro-6'-(2,2-dimethylpropyl)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-c]pyridin]-4'-yl)amino)-1-hydroxyethyl)-3-buten-1-yl)acetamide | 1091624-93-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: N-((1S)-1-((1R)-2-(((4'S)-8'-chloro-6'-(2,2-dimethylpropyl)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-c]pyridin]-4'-yl)amino)-1-hydroxyethyl)-3-buten-1-yl)acetamide
• 英文别名: N-[(2R,3S)-1-[[(4S)-8-chloro-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-c]pyridine-2,1'-cyclobutane]-4-yl]amino]-2-hydroxyhex-5-en-3-yl]acetamide
• CAS: 1091624-93-9
• 化学式: C₂₄H₃₆ClN₃O₃
• 分子量: 450.021
• InChiKey: KIZACQGFZXZGHE-SLFFLAALSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  83.5
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-((1S)-1-((1R)-2-(((4'S)-8'-chloro-6'-(2,2-dimethylpropyl)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-c]pyridin]-4'-yl)amino)-1-hydroxyethyl)-3-buten-1-yl)acetamide 、 甲胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 N-((1S)-1-((1R)-2-(((4'S)-6'-(2,2-dimethylpropyl)-8'-(methylamino)-3',4'-dihydrospiro[cyclobutane-1,2'-pyrano[2,3-c]pyridin]-4'-yl)amino)-1-hydroxyethyl)-3-buten-1-yl)acetamide
  参考文献：
  名称：

  WO2008/147544

  摘要：

  公开号：

文献信息

• Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
  申请人：Zhong Wenge

  公开号：US20090036478A1

  公开（公告）日：2009-02-05

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R 1a , R 1b , R 1c , B, W, R 3 , R 4 and R 5 are defined herein. In another embodiment, the invention provides compounds of general Formula II wherein A 1 , A 2 , A 3 , A 4 , R 1a , R 1b , R 1c , R 2 , R 4 , R 5 , W, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涉及一类新化合物，适用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，该化合物具有一般的I式，其中R1a、R1b、R1c、B、W、R3、R4和R5在此定义。在另一种实施例中，本发明提供了一般式II的化合物，其中A1、A2、A3、A4、R1a、R1b、R1c、R2、R4、R5、W、X和Z在此定义。本发明还包括这些化合物在制药组合物中的使用，用于治疗与Beta-分泌酶蛋白活性相关的疾病和症状。这些疾病包括阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。本发明还包括进一步的II式实施例、中间体和制备I式和II式化合物的有用工艺。
• SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：ZHONG Wenge

  公开号：US20130072483A1

  公开（公告）日：2013-03-21

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R 1a , R 1b , R 1c , B, W, R 3 , R 4 and R 5 are defined herein. In another embodiment, the invention provides compounds of general Formula II wherein A 1 , A 2 , A 3 , A 4 , R 1a , R 1b , R 1c , R 2 , R 4 , R 5 , W, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.

  本发明涉及一类新的化合物，可用于调节β-分泌酶酶活性，并用于治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关病症。在一种实施例中，所述化合物具有一般式I，其中R1a、R1b、R1c、B、W、R3、R4和R5如本文所定义。在另一种实施例中，本发明提供了一般式II的化合物，其中A1、A2、A3、A4、R1a、R1b、R1c、R2、R4、R5、W、X和Z如本文所定义。本发明还包括这些化合物在制药组合物中的使用，用于治疗与β-分泌酶蛋白活性相关的疾病和病症，例如阿尔茨海默病（AD）、认知缺陷和损伤、精神分裂症和其他类似的中枢神经系统疾病。本发明还包括一般式II的进一步实施例、中间体和用于制备一般式I和II化合物的有用过程。
• US8173810B2
  申请人：——

  公开号：US8173810B2

  公开（公告）日：2012-05-08
• US8633315B2
  申请人：——

  公开号：US8633315B2

  公开（公告）日：2014-01-21
• WO2008/147544
  申请人：——

  公开号：——

  公开（公告）日：——